Search
Results
showing 1-10 of 5622
STIWatch Quarterly Newsletter
As many global health fields reassess their reliance on US government funding for research and development, the STI field—already underfunded and reliant on alternate donors—now faces even greater uncertainty. In this newsletter, we share a new STI resource for advocates and highlight the top issues we’re monitoring as events continue to unfold.
Introducing Access Bridge, Our Partner in Product Introduction
AVAC is excited to introduce Access Bridge. Incubated over the past decade at AVAC as part of our Product Introduction and Access team, Access Bridge is an independent, Kenya-based nonprofit organization advancing timely, sustainable and equitable introduction of and access to HIV prevention, sexual reproductive health and related health products.
Global Health Watch: Zimbabwe steps away from US health MoU, new domestic funding in SA, LEN launched in Kenya + Zim, investment case for Global Fund
This week’s issue covers Zimbabwe’s decision to halt negotiations on its Memorandum of Understanding with the US for global health funding; new domestic funding in South Africa; a new investment case for US funding for the Global Fund; the launch of LEN in Kenya and Zimbabwe; and key takeaways from CROI 2026.
CROI 2026: Meaningful Progress, Expanding Choice
AVAC’s continued coverage of CROI summarizes key themes from the final two days of the conference, including the vital importance of choice and steps needed to make choice a reality.
CROI 2026: Science, Solidarity and High Stakes for the HIV Response
CROI 2026 opened with a sobering message and defiant acknowledgment. Against a backdrop of funding cuts, dismantled programs, and growing political interference, speakers on the first two days of CROI warned that interrupting support for HIV research “is not a policy choice; it threatens infrastructures that took decades to build.”
AVAC Infographics for CROI 2026
Going to CROI? AVAC’s up-to-date infographics — on the research & development pipeline, prevention options, and the impact of US funding cuts — are available here for use in conference presentations. We constantly update these graphics, so check back for updates. The latest version of the deck will be available here.
AVAC Year in Review 2025
This report highlights AVAC’s role as a trusted voice, a translator of science and catalyst for action and advocacy. It reflects an organization ready for the future: supporting African leadership, strengthening bridges from R&D to delivery and preparing for a new chapter as we move forward into our fourth decade as an organization.
Global Health Watch: Leadership Changes at US Health Agencies, Global Fund Replenishment and What’s Next for Vaccine Regulation
This week, we reflect on the escalating war on science. Two recent pieces illustrate how budget decisions and policy priorities are reshaping US scientific and global health leadership and undermining the stability of programs relied on by hundreds of millions of people. We also track the consolidation of power across US health agencies, mounting uncertainty in vaccine regulation, and the Global Fund’s ongoing replenishment.
An Overview of Lenacapavir for PrEP Trials
The PURPOSE trials evaluate the safety and efficacy of injectable lenacapavir (LEN), an investigational antiretroviral (ARV) drug being studied as a potential PrEP product. This graphic shows the latest status of all five trials including the groundbreaking results of PURPOSE 1 and PURPOSE 2.
AVAC’s Year in Review
In a year marked by funding freezes, political disruption and historic scientific breakthroughs, we are proud to share our 2025 Year in Review – one defined by crisis and resilience.
showing 1-10 of 5622